APrimary hypercholesterolemia
Second line
Primary hypercholesterolemia
Second line
Preferred second-line agent when targets are not met on a maximum-tolerated statin under 2019. In IMPROVE-IT, adding ezetimibe to simvastatin after acute coronary syndrome reduced cardiovascular events by 6.4% over 7 years, confirming benefit of further LDL lowering. Dose 10 mg once daily with or without food. In statin-intolerant patients, ezetimibe monotherapy is used.
Sources
ICD-10: E78.0 · ICD-11: 5C80.00